EGFR and cancer: The acquired resistance associated with the EGFR T790M mutation can occur by selection of preexisting EGFR T790M+ clones or via genetic evolution of initially EGFR T790M− drug-tolerant cells, suggesting that cancer cells that survive third-generation TKIs may serve as a key reservoir from which acquired resistance can emerge during treatment (68).